The co-primary efficacy endpoints were the change from baseline to Week @ in ( @ ) percentage of parabasal cells in the maturation index ( MI ) , ( @ ) percentage of superficial cells in the MI , ( @ ) vaginal pH , and ( @ ) severity of vaginal dryness .